Noah Goodman Sells 2,000 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Key Points

• Noah Goodman sold 2,000 shares of Kymera on April 10 at an average price of $87.35 for about $174,700 under a pre-arranged Rule 10b5-1 plan to cover tax withholding from vested equity, leaving him with 51,542 shares (a 3.74% reduction).
• He also sold 8,264 shares on April 9 at $87.50 for roughly $723,100, indicating consecutive insider sales at similar prices.
• Kymera shares traded near $85.05 mid-day with a market cap of ~$6.94B; the company missed earnings in its most recent quarter (EPS −$0.97 vs. −$0.77 and revenue $2.87M vs. $14.8M), while analysts' consensus is a "Moderate Buy" with a $118.90 price target.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) insider Noah Goodman sold 2,000 shares of the company's stock in a transaction that occurred on Friday, April 10th. The stock was sold at an average price of $87.35, for a total transaction of $174,700.00. Following the completion of the transaction, the insider owned 51,542 shares in the company, valued at approximately $4,502,193.70. This represents a 3.74% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Noah Goodman also recently made the following trade(s):

• On Thursday, April 9th, Noah Goodman sold 8,264 shares of Kymera Therapeutics stock. The shares were sold at an average price of $87.50, for a total transaction of $723,100.00.

Kymera Therapeutics Price Performance

NASDAQ KYMR traded down $2.30 during mid-day trading on Friday, reaching $85.05. The stock had a trading volume of 399,632 shares, compared to its average volume of 746,582. The stock has a market cap of $6.94 billion, a PE ratio of -23.11 and a beta of 2.28. Kymera Therapeutics, Inc. has a 1 year low of $22.05 and a 1 year high of $103.00. The company has a fifty day moving average price of $82.71 and a 200 day moving average price of $73.02.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its earnings results on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.20). The business had revenue of $2.87 million for the quarter, compared to analysts' expectations of $14.80 million. Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The business's revenue for the quarter was down 60.8% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.88) earnings per share. As a group, equities research analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Jefferies Financial Group assumed coverage on Kymera Therapeutics in a report on Monday, March 16th. They issued a "buy" rating and a $110.00 price objective for the company. BTIG Research lowered their target price on shares of Kymera Therapeutics from $138.00 to $134.00 and set a "buy" rating on the stock in a research note on Thursday, February 26th. B. Riley Financial raised their price target on shares of Kymera Therapeutics from $80.00 to $117.00 and gave the company a "buy" rating in a report on Monday, December 22nd. Citigroup boosted their price objective on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the company a "buy" rating in a report on Monday, March 2nd. Finally, Wall Street Zen downgraded shares of Kymera Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, March 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $118.90.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Baker BROS. Advisors LP boosted its position in Kymera Therapeutics by 30.2% in the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company's stock worth $673,620,000 after purchasing an additional 2,005,813 shares during the last quarter. Avoro Capital Advisors LLC increased its position in shares of Kymera Therapeutics by 17.7% during the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company's stock valued at $581,610,000 after purchasing an additional 1,124,747 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Kymera Therapeutics by 15.6% during the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company's stock valued at $487,685,000 after purchasing an additional 845,922 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Kymera Therapeutics by 20.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company's stock valued at $479,258,000 after purchasing an additional 1,061,957 shares during the last quarter. Finally, BVF Inc. IL lifted its stake in shares of Kymera Therapeutics by 6.6% in the 2nd quarter. BVF Inc. IL now owns 5,502,710 shares of the company's stock worth $240,138,000 after purchasing an additional 340,909 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.